Sherbrooke Park Advisers’s United Therapeutics UTHR Stock Holding History

Sherbrooke Park Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,282	Closed	-$368K	–	727
2025 Q2	$368K	Sell	1,282 -225	-15%	-$67.2K	0.16%	263
2025 Q1	$465K	Sell	1,507 -479	-24%	-$164K	0.22%	156
2024 Q4	$701K	Buy	1,986 +781	+65%	+$287K	0.22%	121
2024 Q3	$432K	Buy	+1,205	New	+$407K	0.1%	370
2024 Q2	–	Sell	-1,148	Closed	-$264K	–	1217
2024 Q1	$264K	Sell	1,148 -5,311	-82%	-$1.2M	0.05%	620
2023 Q4	$1.42M	Buy	6,459 +4,647	+256%	+$1.07M	0.67%	14
2023 Q3	$409K	Sell	1,812 -588	-25%	-$135K	0.13%	283
2023 Q2	$530K	Buy	2,400 +900	+60%	+$199K	0.28%	159
2023 Q1	$336K	Buy	+1,500	New	+$370K	0.51%	83

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Sherbrooke Park Advisers's UTHR Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 1,282 shares — an estimated $368K sold.

Sherbrooke Park Advisers first reported a position in UTHR in Q1 2023 and held it in 9 quarters. The position peaked at $1.42M in Q4 2023. 707 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

Sherbrooke Park Advisers reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 1,282 United Therapeutics shares in Q3 2025, an estimated $368K.
Sherbrooke Park Advisers first reported a position in United Therapeutics in Q1 2023 and held it in 9 quarters.
Sherbrooke Park Advisers's United Therapeutics position peaked at $1.42M in Q4 2023.
707 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.